Liangying Zheng

Liangying Zheng

Auto-generated profile, based on publicly available information

Liangying Zheng

Medical Research Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University 1 , Guangzhou

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
ZQZixi Qin
Zixi Qin
YHYouwei Huang
Youwei Huang
ZLZeying Li
Zeying Li
GPGuopeng Pan
Guopeng Pan
LZLiangying Zheng
Liangying Zheng
FXFan Xing
Fan Xing
Glioblastoma (GBM) is the deadliest form of brain cancer. It is a highly angiogenic and immunosuppressive malignancy. Although immune checkpoint blockade therapies have revolutionized treatment for many types of cancer, their therapeutic efficacy in GBM has been far less than expected or even ineffective. In this study, we found that the genomic signature of glioma-derived endothelial cells (GdEC) correlates with an immunosuppressive state and poor prognosis of patients with glioma. We established an in vitro model of GdEC differentiation for drug screening and used this to determine that cyclic adenosine monophosphate (cAMP) activators could effectively block GdEC formation by inducing oxidative stress. Furthermore, cAMP activators impaired GdEC differentiation in vivo, normalized the tumor vessels, and altered the tumor immune profile, especially increasing the influx and function of CD8+ effector T cells. Dual blockade of GdECs and PD-1 induced tumor regression and established antitumor immune memory. Thus, our study reveals that endothelial transdifferentiation of GBM shapes an endothelial immune cell barrier and supports the clinical development of combining GdEC blockade and immunotherapy for GBM. See related Spotlight by Lee et al., p. 1300

12 September 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
FXFan Xing
Fan Xing
XWXuemei Wang
Xuemei Wang
ZLZeying Li
Zeying Li
LZLiangying Zheng
Liangying Zheng
ZHZuda Huang
Zuda Huang
HZHui Zhang
Hui Zhang
Oncolytic viruses (OVs) have been shown to increase the efficacy of chimeric antigen receptor (CAR) T cells in treating solid tumors. However, their combined effect has been limited by the unbalanced distribution of two agents in tumor tissue and viral infection–mediated CAR-T cell exhaustion. Here, we designed a CAR moiety by inserting the CR2 and CR3 domains (CR2/3-CAR) of low-density lipoprotein receptor, which is the viral receptor of oncolytic vesicular stomatitis virus (VSV) mutant (VSVΔ51), enabling specific loading of VSVΔ51 onto CAR-T cells. The anchored VSVΔ51 could be released from CAR-T cells and efficiently delivered to tumor tissue. Further investigation revealed that the cross-connection between viral envelope proteins and CR2/3-CAR moieties facilitated forming antigen-free CAR clusters and antigen-induced CAR synapse, triggered CAR signaling transduction, and directly pre-activated the CAR-T cells. Consequently, this approach potently enhanced the proliferation, metabolic fitness, and immunological activities of CAR-T cells, and subsequently enhanced the OV/CAR-T synergetic cytotoxicity, revealing an effective strategy for treating solid tumors.

4 October 2023
Verified
Other
Open access
ZQZixi Qin
Zixi Qin
YHYouwei Huang
Youwei Huang
ZLZeying Li
Zeying Li
GPGuopeng Pan
Guopeng Pan
LZLiangying Zheng
Liangying Zheng
FXFan Xing
Fan Xing
Glioblastoma (GBM) is the deadliest form of brain cancer. It is a highly angiogenic and immunosuppressive malignancy. Although immune checkpoint blockade therapies have revolutionized treatment for many types of cancer, their therapeutic efficacy in GBM has been far less than expected or even ineffective. In this study, we found that the genomic signature of glioma-derived endothelial cells (GdEC) correlates with an immunosuppressive state and poor prognosis of patients with glioma. We established an in vitro model of GdEC differentiation for drug screening and used this to determine that cyclic adenosine monophosphate (cAMP) activators could effectively block GdEC formation by inducing oxidative stress. Furthermore, cAMP activators impaired GdEC differentiation in vivo, normalized the tumor vessels, and altered the tumor immune profile, especially increasing the influx and function of CD8+ effector T cells. Dual blockade of GdECs and PD-1 induced tumor regression and established antitumor immune memory. Thus, our study reveals that endothelial transdifferentiation of GBM shapes an endothelial immune cell barrier and supports the clinical development of combining GdEC blockade and immunotherapy for GBM.See related Spotlight by Lee et al., p. 1300

16 September 2024
Verified
Other
Open access
ZQZixi Qin
Zixi Qin
YHYouwei Huang
Youwei Huang
ZLZeying Li
Zeying Li
GPGuopeng Pan
Guopeng Pan
LZLiangying Zheng
Liangying Zheng
FXFan Xing
Fan Xing
Supplementary Table S1 from Glioblastoma vascular plasticity limits effector T-cell infiltration and is blocked by cAMP activation

26 November 2025
Verified
Other
Open access
ZQZixi Qin
Zixi Qin
YHYouwei Huang
Youwei Huang
ZLZeying Li
Zeying Li
GPGuopeng Pan
Guopeng Pan
LZLiangying Zheng
Liangying Zheng
FXFan Xing
Fan Xing
Candidate drugs in the compound library

16 September 2024
Verified
Other
Open access
ZQZixi Qin
Zixi Qin
YHYouwei Huang
Youwei Huang
ZLZeying Li
Zeying Li
GPGuopeng Pan
Guopeng Pan
LZLiangying Zheng
Liangying Zheng
FXFan Xing
Fan Xing
Glioblastoma (GBM) is the deadliest form of brain cancer, characterized as a highly angiogenetic and immunosuppressive malignancy. Although immune checkpoint blockades have revolutionized cancer therapy, their therapeutic efficacy in GBM has been far less than expected or even ineffective. Here, we reveal that the genomic signature of glioma-derived endothelial cells (GdECs) correlates with an immunosuppressive state and poor prognosis of glioma patients. In vitro model of GdECs differentiation is established for drug screening, and we identify that cAMP activators could effectively block the GdECs formation by inducing oxidative stress. cAMP activator impairs the GdECs differentiation in vivo, normalizes the tumor vessels, and alters the immune profile, especially increasing the influx and function of CD8+ effector T cells. The dual blockade of GdECs and PD-1 induces tumor regression and establishes anti-tumor immune memory. Our study reveals that endothelial transdifferentiation of GBM shapes an endothelial immune cell barrier and supports the clinical development of combining GdECs blockade and immunotherapy for GBM.